Programmed cell death protein 1 (PD-1), alternatively referred to as CD279, is an immunoglobulin superfamily member. It is expressed by activated T-cells and plays an important role in subsiding immune responses and promoting tolerance to self-antigens by suppressing T-cell activity. PD-1 has two natural ligands, known as PD-L1 (also known as CD274) and PD-L2 (CD273), that are mainly expressed by antigen presenting cells. Since over-expression of PD-L1 is common in many tumours, several monoclonal antibody therapeutics have been developed to block the PD-1/PD-L1 interaction. These include nivolumab (OPDIVO®) and pembrolizumab (Keytruda®), which have seen clinical success in treating melanoma.
PD-L1 related antibodies from preferred suppliers:
More purified versions of the PD-L1 antibodies:
for more information on the difference between InVivoMAb and InVivoPlus please click HERE!
PD-L1 related proteins from preferred suppliers:
PD-L1 related conjugated proteins:
PD-L1 related ELISA kits from preferred suppliers: